In accordance with 37 C.F.R. § 1.121, please substitute for claim 1 the following rewritten version of the same claim, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

1. (2X Amended) A compound of the formula



wherein

x is from 0 to 2;

R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)

R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,

R^3 is absent when -Y-Z-R^2 is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when

-Y-Z-R^2 is not attached to N;

Y is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



wherein R^5, R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;

or a pharmaceutically acceptable salt thereof.

3. (Amended) The compound of claim 1 or 30 wherein R^2 is selected from phenyl, halophenyl, benzyl, halobenzyl, phenylethyl, halophenylethyl, phenylpropyl, halophenylpropyl, phenylbutyl, halophenylbutyl, tolyl, methoxybenzyl, trifluoromethylbenzyl, halo-methoxybenzyl, phenylbenzyl, adamantanemethyl, adamantaneethyl, adamantanepropyl, cyclohexanemethyl, cyclohexaneethyl, and naphthyl.

4. (2X Amended) The compound of claim 1 or 30 wherein x is 0.

C3

5. (2X Amended) The compound of claim 1 or 30 wherein x is 1 or 2, and R^1 is selected from hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkylamino wherein the alkyl group is optionally substituted by halo.

Please add the following new claims:

C4

--30. (NEW) A compound of the formula



wherein

x is from 0 to 2;

R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)

R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl

groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,

R^3 is absent when -Y-Z-R^2 is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when

-Y-Z-R^2 is not attached to N;

Y is pentylene, hexylene, heptylene, octylene or nonylene; and

Z is



C4 wherein R^5, R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;

or a pharmaceutically acceptable salt thereof.

31. (NEW) A method of treating a patient in need of a sedative, a sleep regulator, an anticonvulsant, a regulator of hypothalamo-hypophyseal secretion, an antidepressant, a modulator of cerebral circulation, treatment of asthma or treatment of irritable bowel syndrome comprising administering to said patient a therapeutically effective amount of H_3 receptor ligand or a pharmaceutically acceptable salt thereof, said H_3 receptor ligand being a compound of the formula



wherein

x is from 0 to 2;

C4

R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)

R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,

R^3 is absent when -Y-Z-R^2 is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when

-Y-Z-R^2 is not attached to N;

Y is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



C 4

wherein R^5, R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;

or a pharmaceutically acceptable salt thereof.

32. (NEW) The method of claim 31, wherein R^2 is selected from phenyl, halophenyl, benzyl, halobenzyl, phenylethyl, halophenylethyl, phenylpropyl, halophenylpropyl, phenylbutyl, halophenylbutyl, tolyl, methoxybenzyl, trifluoromethylbenzyl, halo-methoxybenzyl, phenylbenzyl, adamantanemethyl, adamantaneethyl, adamantanepropyl, cyclohexanemethyl, cyclohexaneethyl, and naphthyl.

33. (NEW) The method of claim 31, wherein x is 0.